Comparing SG&A Expenses: Pfizer Inc. vs Biogen Inc. Trends and Insights

A Decade of SG&A Expenses: Pfizer Inc. vs. Biogen Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Pfizer Inc. and Biogen Inc. have demonstrated distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer consistently outspent Biogen, with its SG&A expenses averaging nearly six times higher. Notably, Pfizer's expenses peaked in 2016, reaching approximately $14.8 billion, before experiencing a dip in 2020, coinciding with global economic shifts. Meanwhile, Biogen's expenses showed a steady increase, peaking in 2021 at around $2.67 billion, reflecting a strategic expansion. This comparison highlights Pfizer's expansive operational scale and Biogen's focused growth strategy. As the industry faces new challenges, these financial insights offer a glimpse into the strategic priorities of these pharmaceutical giants.